

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company nor is it a solicitation of any vote or approval in any jurisdiction.



SoftMedx Healthcare Limited

京玖醫療健康有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 648)

DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcement of the Company dated 3 November 2023. Unless otherwise defined, capitalised terms used in this announcement shall have the same meaning as those defined in the announcement. The circular in relation to the Restructuring Agreement (including the Loan Conversions), the Specific Mandate and the Whitewash Waiver is required to be despatched to the Shareholders within 21 days after the date of the announcement pursuant to Rule 8.2 of the Takeovers Code. As additional time is required for the Company to finalise certain financial information and confirmations in the circular, an application has been made to the Executive for, and the Executive has indicated that it is minded to grant its consent to a waiver from strict compliance with Rule 8.2 of the Takeover Code and to extend the time for the despatch of the circular to the Shareholders from 24 November 2023 to no later than 8 December 2023.

GENERAL

Trading in the shares of the Company will continue to be suspended pending fulfilment of the Resumption Conditions. The Company will keep its shareholders and potential investors posted of any material development in this regard as and when appropriate.

Shareholders and potential investors of the Company should exercise caution when dealing in the Shares.

For and on behalf of the board of
SoftMedx Healthcare Limited
Lam Sung Him Gaston
Company Secretary

Hong Kong, 24 November 2023

As at the date of this announcement, the Board comprises Mr. Cheung Wai Kwan and Mr. Wang Jianguo as executive Directors; and Ms. Hu Xuezhen, Mr. Lin Pinzhuo and Mr. Yiu Chun Wing as independent non-executive Directors.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement (other than those relating to the Investor) and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement (other than those expressed by the sole director of the Investor) have been arrived at after due and careful consideration and there is no other fact not contained in this announcement, the omission of which would make any statement in this announcement misleading.

The sole director of the Investor, Mr. Huang, accepts full responsibility for the accuracy of the information relating to the Investor contained in this announcement (other than those relating to the Group) and confirms, having made all reasonable enquiries, that to the best of his knowledge, opinions expressed in this announcement (other than those expressed by the Directors) have been arrived at after due and careful consideration and there is no other fact not contained in this announcement, the omission of which would make any statement in this announcement misleading.